XML 32 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1
Inventories, Net
 12 Months Ended
Dec. 31, 2024
Inventory Disclosure [Abstract]  
Inventories, Net Inventories, Net
The Company's net inventories consisted of the following as of December 31:
20242023
Raw materials$11,982,045 $12,619,092 
Consigned inventory126,090 149,701 
Finished goods, net of reserve2,897,359 4,645,098 
Total inventories15,005,494 17,413,891 
less non-current inventories(11,005,499)(12,804,529)
Total inventories classified as current$3,999,995 $4,609,362 
The Company's non-current inventories consisted of the following as of December 31:
20242023
Vibativ Raw Materials$6,180,347 $6,611,426 
Vibativ Finished Goods183,057 810,454 
Kristalose Raw Materials2,672,720 3,263,515 
Vaprisol Raw Materials1,172,849 1,170,641 
Caldolor Finished Goods77,382 67,307 
Sancuso Raw Materials458,684 574,502 
Acetadote Raw Materials23,915 — 
Omeclamox69,622 — 
Study Drug Raw Materials166,923 203,383 
Other Products— 103,300 
Total non-current inventory$11,005,499 $12,804,529 
The Company purchases the active pharmaceutical ingredient (“API”) for Kristalose and maintains the inventory of that raw material. API for the Company's Vaprisol and Vibativ brands were included in the assets associated with the acquisition of those brands and are also included in the raw materials inventory. As part of the Vibativ acquisition, the Company acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition. Consigned inventory represents Authorized Generic inventory stored with Padagis until shipment.
At December 31, 2024 and 2023, there were no cumulative obsolescence or discontinuance losses necessary to recognize.